Evidence map›Paper›PMID 42851332›Full record

ArticleFrontiers in cellular and infection microbiology2026

Resistance to novel antimicrobial agents among NDM-and OXA-48-producing Carbapenem-resistant Enterobacterales in Lebanon.

George F Araj, Joseph M Matar, Chaza K Al Ghor, Ghena M Sobh, Clara R Dagher

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in cellular and infection microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

George F ArajClinical Microbiology Laboratory, Department of Pathology and Laboratory Medicine, American University of Beirut Medical Center, Beirut, Lebanon.
Joseph M MatarDepartment of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon.
Chaza K Al GhorClinical Microbiology Laboratory, Department of Pathology and Laboratory Medicine, American University of Beirut Medical Center, Beirut, Lebanon.
Ghena M SobhClinical Microbiology Laboratory, Department of Pathology and Laboratory Medicine, American University of Beirut Medical Center, Beirut, Lebanon.
Clara R DagherClinical Microbiology Laboratory, Department of Pathology and Laboratory Medicine, American University of Beirut Medical Center, Beirut, Lebanon.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Rapid detection of carbapenemases and antimicrobial susceptibility testing (AMST) against carbapenem-resistant (CR) Enterobacterales (CRE) are key elements in controlling their nosocomial spread and useful to guide treatment of patients infected with such morbid pathogens. The absence of comprehensive data in Lebanon prompted this study. Objective: This study aimed at revealing the carbapenemase types among CR isolates recovered from patients representing 100 Methods: Identification of isolates was done by MALDI-TOF, and the types of carbapenemases were determined by the rapid NG-Test CARBA. Antimicrobial resistance (AMR) profiles were revealed against the routine antibiotics, including ceftazidime-avibactam, and novel antimicrobial agents that still have not been introduced in this country, namely, imipenem-relebactam, meropenem-vaborbactam, and cefiderocol using disk diffusion and standard Etest methods. Results: Among both CREc and CRKp, the detected carbapenemases were only NDM and OXA-48, whereby the majority were NDM. The activity of novel antimicrobial agents was higher against CREc than CRKp isolates, and against OXA-48- producing strains than NDM-producing strains in both species. Conclusion: This first comprehensive

Indexed as

Anti-Bacterial AgentsBacterial Proteinsbeta-LactamasesCarbapenem-Resistant EnterobacteriaceaeEscherichia coliKlebsiella pneumoniaeAzabicyclo CompoundsCarbapenemsCefiderocolCeftazidimeDrug CombinationsDrug Resistance, Multiple, BacterialEnterobacteriaceae InfectionsEscherichia coli InfectionsHumansKlebsiella InfectionsAnti-Bacterial Agentsavibactam, ceftazidime drug combinationAzabicyclo CompoundsBacterial Proteinsbeta-LactamasescarbapenemaseCarbapenemsCefiderocolCeftazidimeDrug CombinationsThird Generation Cephalosporinsantimicrobial resistancecarbapenemasescarbapenem- resistant EnterobacteralesNG-Test CARBA-5Novel antibiotics

Identifiers

PMID42851332
PMCPMC13645548

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.